What type of study is this?

September 16, 2025European PsychiatryOpen Access

Efficacy and safety of vortioxetine in cardiological patients

View Full Paper

Ask AI

Bookmark

At the end of 8 weeks, 89% of patients exhibited substantial clinical improvement with vortioxetine.
Patients reported enhanced quality of life and reduced depressive symptoms based on multiple evaluation scales.
The treatment had good tolerability with only 13.5% experiencing mild side effects like dizziness and nausea.
Significant improvements were seen in cardiovascular indicators, including reduced angina attacks and arrhythmias.

No takes yet. Share an insight, caveat, or question.

Observational analysis shows significant improvement in depressive disorders in cardiological patients, suggesting vortioxetine's dual benefits.

Schelchkova et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows significant improvement in depressive disorders in cardiological patients, suggesting vortioxetine's dual benefits.